Author

Mavis Mensah

Observed names: M Mensah, M. Mensah, M.O. Mensah, Mavis O. Mensah, Mensah Mavis

Institution: University of Ghana

Observed institutions: University of Ghana, University Hospital Coventry, Fondazione IRCCS Istituto Nazionale dei Tumori

ORCID: 0000-0003-2259-421X

Observed ORCID: 0000-0003-2259-421X

OpenAlex ID: A5000440596

Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study

2019 · Mattia Boeri, Massimo Milione, et al. · Clinical Cancer Research · 84

Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction

2014 · O Fortunato, M Boeri, et al. · Cell Death and Disease · 82

Assessment of Circulating microRNAs in Plasma of Lung Cancer Patients

2014 · Orazio Fortunato, Mattia Boeri, et al. · Molecules · 75

Diagnostic role of circulating extracellular matrix-related proteins in non-small cell lung cancer

2018 · Francesca Andriani, Elena Landoni, et al. · BMC Cancer · 57

MiR-16 regulates the pro-tumorigenic potential of lung fibroblasts through the inhibition of HGF production in an FGFR-1- and MEK1-dependent manner

2018 · Francesca Andriani, Maria Teresa Majorini, et al. · Journal of Hematology & Oncology · 37

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening

2017 · Mavis Mensah, Cristina Borzi, et al. · Journal of Visualized Experiments · 35

Cotargeting of miR‐126‐3p and miR‐221‐3p inhibits PIK3R2 and PTEN, reducing lung cancer growth and metastasis by blocking AKT and CXCR4 signalling

2021 · Daniela Di Paolo, Francesca Pontis, et al. · Molecular Oncology · 33

Circulating extracellular vesicles from individuals at high-risk of lung cancer induce pro-tumorigenic conversion of stromal cells through transfer of miR-126 and miR-320

2021 · Francesca Pontis, Luca Roz, et al. · Journal of Experimental & Clinical Cancer Research · 28

Age-Related Alterations in Immune Contexture Are Associated with Aggressiveness in Rhabdomyosarcoma

2019 · Patrizia Gasparini, Orazio Fortunato, et al. · Cancers · 27

MiR-486-5p Targets CD133+ Lung Cancer Stem Cells through the p85/AKT Pathway

2022 · Massimo Moro, Orazio Fortunato, et al. · Pharmaceuticals · 25

Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system

2020 · Arsela Prelaj, Claudia Proto, et al. · Translational Lung Cancer Research · 11

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening

2017 · Mavis Mensah, Cristina Borzi, et al. · Journal of Visualized Experiments · 11

Effect of Small‐Quantity Lipid‐Based Nutrient Supplementation on Children's Cortisol Concentration

2026 · Helena Nti, Paul D. Hastings, et al. · Maternal and Child Nutrition

Economic, socio-emotional, and food security conditions during COVID-19 pandemic among caregivers of young adolescents aged 10–12 yrs in a semi-urban setting in Ghana

2026 · Mavis O. Mensah, Ebenezer Adjetey, et al. · BMC Public Health

Figure S2 from Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study

2023 · Mattia Boeri, Massimo Milione, et al.

Figure S3 from Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study

2023 · Mattia Boeri, Massimo Milione, et al.

Figure S1 from Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study

2023 · Mattia Boeri, Massimo Milione, et al.

Supplementary Tables from Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study

2023 · Mattia Boeri, Massimo Milione, et al.

Data from Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study

2023 · Mattia Boeri, Massimo Milione, et al.

Data from Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study

2023 · Mattia Boeri, Massimo Milione, et al.

Supplementary Tables from Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study

2023 · Mattia Boeri, Massimo Milione, et al.

Figure S1 from Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study

2023 · Mattia Boeri, Massimo Milione, et al.

Figure S3 from Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study

2023 · Mattia Boeri, Massimo Milione, et al.

Figure S2 from Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study

2023 · Mattia Boeri, Massimo Milione, et al.

Author response for "Co‐targeting of miR‐126‐3p and miR‐221‐3p inhibits PIK3R2 and PTEN, reducing lung cancer growth and metastasis by blocking AKT and CXCR4 signaling"

2021 · Daniela Di Paolo, Francesca Pontis, et al.

Works count: 31

Citation count: 505

H-index: 11

I10-index: 12